Legal & General Group’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-175
| Closed | -$3.04K | – | 3525 |
|
|
2024
Q1 | $3.04K | Sell |
175
-102
| -37% | -$1.77K | ﹤0.01% | 3331 |
|
|
2023
Q4 | $4.33K | Sell |
277
-1,300
| -82% | -$20.3K | ﹤0.01% | 3334 |
|
|
2023
Q3 | $78K | Buy |
1,577
+72
| +5% | +$3.56K | ﹤0.01% | 2842 |
|
|
2023
Q2 | $118K | Buy |
1,505
+795
| +112% | +$62.2K | ﹤0.01% | 2819 |
|
|
2023
Q1 | $64.3K | Buy |
710
+28
| +4% | +$2.54K | ﹤0.01% | 2836 |
|
|
2022
Q4 | $80.5K | Buy |
682
+50
| +8% | +$5.9K | ﹤0.01% | 2863 |
|
|
2022
Q3 | $114K | Buy |
632
+70
| +12% | +$12.6K | ﹤0.01% | 2779 |
|
|
2022
Q2 | $50K | Buy |
562
+15
| +3% | +$1.34K | ﹤0.01% | 3001 |
|
|
2022
Q1 | $85K | Buy |
547
+6
| +1% | +$932 | ﹤0.01% | 2905 |
|
|
2021
Q4 | $161K | Hold |
541
| – | – | ﹤0.01% | 2795 |
|
|
2021
Q3 | $312K | Buy |
541
+305
| +129% | +$176K | ﹤0.01% | 2554 |
|
|
2021
Q2 | $107K | Buy |
236
+69
| +41% | +$31.3K | ﹤0.01% | 2711 |
|
|
2021
Q1 | $90K | Buy |
167
+46
| +38% | +$24.8K | ﹤0.01% | 2648 |
|
|
2020
Q4 | $106K | Buy |
121
+33
| +38% | +$28.9K | ﹤0.01% | 2575 |
|
|
2020
Q3 | $55K | Buy |
+88
| New | +$55K | ﹤0.01% | 2665 |
|